Mallinckrodt initiates rolling submission of nda to the u.s. fda for terlipressin

Mallinckrodt initiates rolling submission of new drug application to the u.s. food and drug administration (fda) for terlipressin for the treatment of patients with hepatorenal syndrome type 1 (hrs-1).mallinckrodt - expects to complete submission of nda in coming months for terlipressin.
MNK Ratings Summary
MNK Quant Ranking